Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arzoxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 20/20 | 0.98 |
| ▸ | ESR2 known ✓ | Q92731 | 19/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | GMNN | O75496 | 1/20 | 0.66 |
| ▸ | HLA-A | P04439 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | UBE2N | P61088 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | PLD2 | O14939 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arzoxifene SCHEMBL29351083 | 1.00 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Arzoxifene SCHEMBL5493113 | 0.99 | ESR1 (0.96) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Arzoxifene SCHEMBL285277 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Arzoxifene SCHEMBL29354336 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Arzoxifene SCHEMBL5970803 | 0.98 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Arzoxifene SCHEMBL1649149 | 0.97 | ESR1 (0.96) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL7460587 | 0.94 | ESR1 (0.88) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL3807019 | 0.94 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL7450925 | 0.94 | ESR1 (0.89) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL8467028 | 0.94 | ESR1 (0.86) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757291-A2 | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof | Eli Lilly & Company (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1357903-B1 | STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4- 2-(PIPERIDIN-1-YL) ETHOXY|PHENOXY)-2-(4-METHOXYPHENYL) BENZO b|THIOPHENE AND SALTS THEREOF | LILLY CO ELI (US) | 2006-12-20 | — | — | EP | claimed |
| US-7122203-B2 | Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof | ELI LILLY AND COMPANY (US) | 2006-10-17 | — | — | US | claimed |
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | claimed |
| US-20040014672-A1 | Novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride | LUKE WAYNE DOUGLAS (US) | 2004-01-22 | — | — | US | claimed |
| US-6653479-B1 | Cardiovascular, nervous system, bone, and muscular disorders; hyperlipidemia, osteoporosis, endometriosis, uterine fibrosis, benign prostatic hyperplasia, and Alzheimer*s treatment; anticarcinogenic agents | ELI LILLY AND COMPANY | 2003-11-25 | — | — | US | claimed |
| EP-1204655-B1 | A CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL)BENZO[B]THIOPHENE HYDROCHLORIDE | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | claimed |
| US-6610706-B1 | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | claimed |
| US-20030119875-A1 | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof | ELI LILLY AND COMPANY | 2003-06-26 | — | — | US | claimed |
| US-6258826-B1 | HALOGEN SUBSTITUTED BENZOTHIOPHENE COMPOUNDS WITH CARRIERS | ELI LILLY AND COMPANY | 2001-07-10 | — | — | US | claimed |
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | ENDORECHERCHE, INC. | 2023-02-14 | — | — | US | disclosed |
| US-10342805-B2 | Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators | ENDORECHERCHE, INC. (CA) | 2019-07-09 | — | — | US | disclosed |
| US-9744177-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | ENDORECHERCHE, INC. (CA) | 2017-08-29 | — | — | US | disclosed |
| US-20150250802-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | ENDORECHERCHE, INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| US-20130244989-A1 | TREATMENT OF ALZHEIMER'S DISEASE, LOSS OF COGNITION, MEMORY LOSS AND DEMENTIA WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ENDORECHERCHE, INC. (CA) | 2013-09-19 | — | — | US | disclosed |
| US-5986109-A | UROGENITAL DISORDERS, CARDIOVASCULAR DISORDERS AND ANTICARCINOGENIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-11-16 | — | — | US | disclosed |
| US-5981765-A | FOR TREATMENT OF POST-MENOPAUSAL SYNDROME INCLUDING OSTEOPOROSIS, CARDIOVASCULAR EFFECTS SUCH AS HYPERLIPIDEMIA, AND ESTROGEN-DEPENDENT CANCER, PARTICULARLY BREAST AND UTERINE CANCER | ELI LILLY AND COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| US-5977093-A | INHIBITING ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5969142-A | OXIDIZING SULFUR ATOM OF SUBSTITUTED BENZOTHIOPHENE, REACTING PRODUCT WITH NUCLEOPHILIC GROUP, REDUCING PRODUCT TO DESIRED COMPOUND | ELI LILLY AND COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0729956-A1 | Benzothiophene compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119875-A1 | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof | TPMT, BHMT2, TST | ESR1 4324/4885ESR2 3666/4885MEN1 2791/4885 |
| US-20150250802-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | SHBG, CYP19A1, AR | ESR1 52/4885ESR2 46/4885MEN1 837/4885 |
| US-10342805-B2 | Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators | BRCA1, SHBG, CYP19A1 | ESR1 5/4885ESR2 6/4885MEN1 224/4885 |
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | SHBG, ESRRA, ESR2 | ESR1 8/4885ESR2 3/4885MEN1 3108/4885 |
| US-20130244989-A1 | TREATMENT OF ALZHEIMER'S DISEASE, LOSS OF COGNITION, MEMORY LOSS AND DEMENTIA WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | BRCA1, SHBG, CYP19A1 | ESR1 5/4885ESR2 6/4885MEN1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.